Front Page

Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC)

Tasquinimod clinical development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

Active Biotech presentation at Aktiespararnas “Aktiedag Lund” (in Swedish)

Analys Active Biotech: Ny plan för ögonstudie (in Swedish)

Active Biotech AB Interim report January – June 2021

Active Biotech provides status update of its clinical naptumomab project

Active Biotech: CEO Helen Tuvesson presents at Redeye Growth Day 2021 (Swedish)

Active Biotech’s presentation at ABGSC Life Science Summit May 25 2021

Annual General Meeting of Active Biotech AB

Active Biotech’s presentation at “Aktiedagen” May 4, 2021 (Swedish shareholders’ association, in Swedish)

Aktiespararna initiate coverage of Active Biotech

Annual Report 2020 Active Biotech AB (publ)

Active Biotech AB Interim report January – March 2021


Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab

Active Biotech’s presentation at Solebury Trout European Biotech Investor Days 2021

Number of shares and votes in Active Biotech

Number of shares and votes in Active Biotech

Active Biotech Year-end report January – December 2020

Active Biotech enters into a manufacturing agreement with Famar Health Care Services for new formulation of Laquinimod

Active Biotech’s rights issue heavily oversubscribed

Adjustment of period for trading in subscription rights and interim shares in Active Biotech’s rights issue

Active Biotech publishes prospectus and certain new financial information included in the prospectus

Redeye initiates coverage of Active Biotech, see analysis

Active Biotech Receive Milestone Payment From NeoTX

Active Biotech’s presentation at Life Science Day 2020 (in Swedish)

Active Biotech’s nomination committee appointed

Report from extraordinary general meeting in Active Biotech and adjustment of previously communicated timetable for the rights issue

Active Biotech announces the final terms of the rights issue

Active Biotech updates its clinical strategy and projected milestones

Invitation to Active Biotech’s virtual capital markets day

Notice of extraordinary general meeting in Active Biotech

Active Biotech carries out rights issue

Active Biotech Interim report January – September 2020

Active Biotech announces first patient dosed in phase 1b/2a study of tasquinimod use in treatment of multiple myeloma